CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.64BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.04xvs all stocks
52-Week Change
-63.26%vs all stocks
Market Capitalization
1.64BUSDvs all stocks (USD)
Enterprise Value
1.19BUSDvs all stocks (USD)
Forward P/E
-5.74xvs Biotechnology peers
Price to Book (MRQ)
5.59xvs Biotechnology peers
Enterprise to EBITDA
-4.51xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-36.66%vs Biotechnology peers
Return on Equity (TTM)
-77.85%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-264.29MUSDvs all stocks (USD)
Net Income (TTM)
-257.08MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-224.15MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-135.94MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-244.83MUSDvs all stocks (USD)
Pre-tax Income
-229.71MUSDFY2025 · Dec 31, 2025Income Tax Expense
611.00KUSDFY2025 · Dec 31, 2025Net Income
-230.32MUSDFY2025 · Dec 31, 2025EBIT
-222.46MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-219.85MUSDFY2025 · Dec 31, 2025Research & Development
202.86MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.97MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.25MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.53USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.53USDFY2025 · Dec 31, 2025Basic Shares Outstanding
64.46MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
64.46MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-230.32MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
3.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-219.66MUSDFY2025 · Dec 31, 2025Free Cash Flow
-219.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
334.52MUSDFY2025 · Dec 31, 2025Interest Paid
5.06MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-230.32MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.62MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.90MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.02MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.02MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.81MUSDFY2025 · Dec 31, 2025Capital Expenditures
-35.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-265.37MUSDFY2025 · Dec 31, 2025Sale of Investments
468.40MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
202.99MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
73.02MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
145.42MUSDFY2025 · Dec 31, 2025Shares Outstanding
72.13MSharesUpdated Jul 19, 2026Float Shares
43.64MSharesUpdated Jul 19, 2026Shares Short
6.56MSharesUpdated Jul 19, 2026Short Ratio
5.02daysvs all stocks
Short % of Shares Outstanding
10.89%vs all stocks
% Held by Insiders
8.42%vs all stocks
% Held by Institutions
78.26%vs all stocks
Total Cash (MRQ)
357.92MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.86USDUpdated Jul 19, 2026Total Debt (MRQ)
100.80MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3968xvs Biotechnology peers
Current Ratio (MRQ)
8.60xvs Biotechnology peers
Book Value per Share (MRQ)
3.52USDUpdated Jul 19, 2026Total Assets
424.43MUSDvs all stocks (USD)
Total Current Assets
421.69MUSDFY2025 · Dec 31, 2025Total Liabilities
119.95MUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.74MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
74.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
45.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
334.52MUSDFY2025 · Dec 31, 2025Other Short-term Investments
59.45MUSDFY2025 · Dec 31, 2025Accounts Payable
28.43MUSDFY2025 · Dec 31, 2025Short-term Debt
1.23MUSDFY2025 · Dec 31, 2025Long-term Debt
74.47MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-462.91MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
304.48MUSDvs all stocks (USD)
52-Week Low
5.95USDUpdated Jul 19, 202652-Week High
62.75USDUpdated Jul 19, 202652-Week Change
-63.26%vs all stocks
Beta
1.04xvs all stocks
50-Day MA
18.78USDUpdated Jul 19, 2026200-Day MA
15.65USDUpdated Jul 19, 2026Avg 10-Day Volume
1.26MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.34MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-4.02USDUpdated Jul 19, 2026Other Income / Expense
22.37MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.61
Altman Z-Score 6.03: safe zoneNotable
Altman Z-Score: 6.03
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.64B, above the global median of $1.15BNotable
Market cap (USD): 1,644,493,960Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Porton Pharma Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Henan Lingrui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inner Mongolia Furui Medical Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Balance Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alembic Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ningbo Menovo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cofoe Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule